Abstract:BACKGROUNDAlzheimer's disease (AD) has high a prevalence rate, high medical costs, and care difficulties, and has become a serious social and economic problem in our aging society. So far, there has not been a reliable and objective diagnostic criteria for AD found. In recent years, there have been many domestic and foreign studies on the biological markers of cerebrospinal fluid in the patients with AD, and high levels of the T-tau, P-tau found in cerebrospinal fluid (CSF) is at this point an indisputable fact. However, the relationship between these markers and the severity of dementia, as well as the development of the disease, should be further studied.OBJECTIVECompare the CSF level of total tau (T-tau) and phosphorylated tau at threonine 231 (P-tau231) between patients with moderate to severe Alzheimer's disease (AD) and those with vascular dementia (VD) at baseline, and 6 month follow-up. Observe the differences between patients with AD and control group, as well as the changes as the disease develops.METHODSThere were 11 patients with moderate AD (10 ≤ MMSE ≤ 20), 10 patients with severe AD (MMSE ≤ 9), and 7 age-matched patients with severe VD at baseline, among which 7 AD patients and 6 VD patients completed the 6 months follow-up. CSF levels of T-tau, P-tau231 were measured with sandwich ELISA.RESULTAt baseline, the concentrations of the CSF level of T-tau were 470.08 (263.58) pg/mL in the AD group and 208.76 (42.24) pg/mL in the VD group. This difference was statistically significant (Z= -3.369, p <0.001). The concentrations of CSF level of P-tau231 were 90.94 (49.86) pg/mL in the AD group and 42.96 (13.10) pg/mL in the VD group. This difference was also statistically significant (Z = -3.237, p <0.001). Compared to patients with severe VD, the concentration of CSF T-tau in patients with severe AD was significantly higher (Z= -2.830, p = 0.005), as well as the concentration of CSF P-tau231 (Z = -2.392, p = 0.017). The concentration of CSF P-tau231 in the patients with moderate AD was significantly higher than that in the patients with severe VD (Z = -2.605, p = 0.009). At the 6 months follow-up, there were no statistically significant differences in the changes of CSF T-tau and CSF P-tau231 concentrations between the AD group and VD group.CONCLUSIONThe CSF level of T-tau and P-tau231 in the AD patients was significantly higher than that in the VD patients. The concentration of CSF P-tau231 in the moderate AD patients was significantly higher than that in the patients with severe AD. During the 6 months follow-up, the changes of the CSF concentrations of T-tau and P-tau231 between AD group and VD group were not statistically significant.

Alzheimer's-Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid

Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches

CSF Proteomics in Patients With Progressive Supranuclear Palsy

Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases

Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy

Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy

Dominance of Tau Burden in Cortical Over Subcortical Regions Mediates Glymphatic Activity and Clinical Severity in PSP

Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription

Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy

Tau protein profiling in tauopathies: a human brain study

Association of Insulin-like Growth Factor-1 and Neurofilament Light Chain in Patients with Progressive Supranuclear Palsy

Progressive Supranuclear Palsy: What Do We Know about It?

Cerebral tau deposition in co-morbid progressive supranuclear palsy and amyotrophic lateral sclerosis: an [18F]-flortaucipir and 7T MRI study

Cerebrospinal Fluid Total and Phosphorylated Tau Protein in Behavioral Variant Frontotemporal Dementia, Progressive Supranuclear Palsy, Corticobasal Syndrome and Non-Fluent Agrammatic Primary Progressive Aphasia: A Systematic Review and Meta-Analysis

High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer’s Disease

Linking PI-2620 tau-PET, fluid biomarkers, MRI, and cognition to advance diagnostics for progressive supranuclear palsy

A Pilot Longitudinal Study on Cerebrospinal Fluid (CSF) Tau Protein in Alzheimer's Disease and Vascular Dementia.

S3-02-04 Neuroserpin provides a structural model for the causation and rational therapy of dementia